LIVN - LivaNova PLC

LivaNova PLC is a medical device company whose primary products are the VNS Therapy system (vagus nerve stimulator) for drug-resistant epilepsy and depression, and cardiopulmonary bypass machines used in open-heart surgery. Its customers are hospitals, neurology clinics, and cardiac surgery centers, operating under a capital equipment plus disposables business model with recurring revenue from consumables and replacement leads. Annual revenue is approximately $1.2B, with primary markets in the United States and Western Europe. The company is headquartered in London and listed on NASDAQ.

Past Year Trends

• LivaNova's Neuromodulation segment revenue grew approximately 9% year-over-year in FY2024 to roughly $906 million, driven by continued U.S. VNS Therapy implant volume for drug-resistant epilepsy and expanding commercial payer coverage for treatment-resistant depression. (Bullish)
• A U.S. federal district court ruled in LivaNova's favor in 2024, finding CMS's 2019 National Coverage Determination denying Medicare reimbursement for VNS Therapy in treatment-resistant depression was arbitrary and capricious, and ordered CMS to issue a new coverage determination. (Bullish)
• LivaNova's Cardiopulmonary segment faced flat-to-declining revenue in FY2024 as constrained hospital capital spending weighed on heart-lung machine and oxygenator sales, compressing blended company margins and diluting the faster-growing Neuromodulation contribution. (Bearish)

Next Year Trends

• CMS is under court mandate to issue a new National Coverage Determination for VNS Therapy in treatment-resistant depression; a favorable ruling would unlock Medicare reimbursement for an estimated 3 million U.S. TRD patients and could materially accelerate Neuromodulation implant volumes. (Bullish)
• LivaNova's next-generation closed-loop SenTiva DUO VNS device, designed to auto-adjust stimulation based on detected cardiac biomarkers, faces ongoing FDA review; clearance would trigger a U.S. replacement cycle across the existing implanted base and support average selling price improvement. (Bullish)
• Approximately 35% of LivaNova's revenue is generated outside the U.S. in EUR and GBP-denominated markets; sustained U.S. dollar strength against European currencies would create a structural revenue and margin headwind in reported USD results without a natural hedge offsetting it. (Bearish)

Red Flags

No severe red flags identified as of August 2025.